Publications by authors named "Geert D'Haens"

Claim this Profile
V
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
Geert R D'Haens, Mark Löwenberg, Filip Baert, Peter Bossuyt, Tamás Molnár

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
Vipul Jairath, Silvio Danese, Geert R D'Haens, Brian G Feagan, Laurent Peyrin-Biroulet

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of Sphingosine-1-phosphate receptor modulator treatment on leukocyte subsets across different clinical indications: A systematic review.
Dimitrios Nikolakis, Christoph Teichert, Joep Grootjans, Marleen G H van de Sande, Geert R D'Haens

Autoimmun Rev· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of intestinal ultrasound and shear-wave elastography to assess early response in ulcerative colitis patients treated with filgotinib.
Maarten Jan Pruijt, Christoph Teichert, Floris Antonius De Voogd, Reimer Jacques Janssen, Mark Löwenberg, Geert Renaat D'Haens

J Crohns Colitis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Mesalazine and Ozanimod following Induction Treatment in Mesalazine-Exposed Advanced Therapy-Naïve Adult Ulcerative Colitis Patients.
Geert D'Haens, Ekaterina Safroneeva, Laurent Peyrin-Biroulet, Silvio Danese, Vipul Jairath

Inflamm Intest Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Silvio Danese, Bruce E Sands, Brian G Feagan, Vipul Jairath, Remo Panaccione, Geert R D'Haens

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Submucosal hyper-echogenicity on intestinal ultrasound is associated with fat deposition and predicts treatment non-response in patients with ulcerative colitis.
Maarten J Pruijt, E Andra Neefjes-Borst, Floris A E De Voogd, Marilyne M Lange, Christoph Teichert, Geert R D'Haens

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucosal kinase activity and inflammatory profiles in inflammatory bowel disease, and in relation to tofacitinib response.
Eelco C Brand, Britt Roosenboom, Lisanne Lutter, Bea Malvar Fernandez, Savithri Rangarajan, Geert R D'Haens

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease - Authors' reply.
Andrew Y F Li Yim, Evgeni Levin, Wouter J de Jonge, Peter Henneman, Jack J Satsangi, Geert R D'Haens

Lancet Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial transcriptomics and immunophenotyping uncover chronic inflammation-induced immune adaptations favoring dysplasia development in patients at risk of colitis-associated cancer.
Sofía Frigerio, Hina N Khan, Mojtaba Amini, Bregje Mol, Andra Neefjes-Borst, Geert R D'Haens

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
Marla C Dubinsky, Geert D'Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-survey.
Paula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, Mafalda Santiago, Walter Reinisch, Geert D'Haens, Geert D'Haens

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease.
Virginia Solitano, Jurij Hanžel, Christopher Ma, Robert Battat, Tim Raine, Geert D'Haens

EClinicalMedicine· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease.
Suzanne I Anjie, Geert R D'Haens, Filip Baert, Peter Bossuyt, Frank Hoentjen

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.
Sudheer Kumar Vuyyuru, Jurij Hanzel, Mantaj S Brar, Silvio Danese, Geert D'Haens

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucosal B Cell Expansion and Maturation Contribute to Colitis Pathogenesis.
Ivan C N Fung, Pim J Koelink, Lieven G M Mulders, Iris Admiraal, Caroline Verseijden, Geert R D'Haens

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study.
Bruce E Sands, Stefan Schreiber, Marla C Dubinsky, Geert D'Haens, Bincy P Abraham

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants.
Yuki Otani, Christopher D Payne, Edward V Loftus, Geert D'Haens, Shomron Ben Horin

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Should an IBD Prevention Trial Be Designed?
Rogier L Goetgebuer, Ryan C Ungaro, Brian G Feagan, Vipul Jairath, Jean-Frédéric Colombel, Geert R A M D'Haens

Inflamm Bowel Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transmural healing in ulcerative colitis patients improves long-term outcomes compared to endoscopic healing alone.
Chong-Teik Lim, Christoph Teichert, Maarten Pruijt, Floris De Voogd, Geert D'Haens

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory single-cell analysis of peripheral blood mononuclear cells from vedolizumab-treated Crohn's disease patients identifies response-associated differences among the plasmacytoid dendritic cells and classical monocytes.
Andrew Yung Fong Li Yim, Ishtu Hageman, Vincent W Joustra, Ahmed M I M Elfiky, Mohammed Ghiboub, Geert R D'Haens

Front Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn's Disease Postoperative Recurrence in the PREVENT trial.
Jurij Hanzel, Sudheer K Vuyyuru, Brian Bressler, Mark A Samaan, Malcolm Hogan, Geert R D'Haens

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's Disease.
Zhigang Wang, Yannick Hoffert, Wei Zhang, Wannee Kantasiripitak, Bram Verstockt, Geert D'Haens

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug repurposing approach for the discovery of therapeutic agents for Crohn's disease-associated intestinal fibrosis.
Dimitrios Nikolakis, Andrew Y F Li Yim, Kenneth L Overberg, Mohammed Ghiboub, Manon E Wildenberg, Geert R D'Haens

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNF inhibitors affect the induction and maintenance of spike-specific B-cell responses after mRNA vaccination.
Laura Yl Kummer, Lisan H Kuijper, Laura Fernández Blanco, Amélie Bos, Christine Kreher, Geert Ram D'Haens

RMD Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis